US FDA's Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication. Echols RM, Nagata T. Clin Infect Dis 2021;73:751-752.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Echols RM, Nagata T. US FDA's Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication. Clin Infect Dis 2021;73:751-752.
PMID: 34398951